Shanghai Pioneer Holding (HKSE:01345) FFO

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:01345 Shanghai Pioneer Holding Ltd HKSE:01345
73 GF Score
Price HK$2.15
GF Value HK$1.80
Valuation Modestly Overvalued
! 8 Warning Signs
View Full Analysis

What is Shanghai Pioneer Holding FFO?

FFO (Funds from operations) only applies to REITs.

HKSE:01345
73GF Score
Shanghai Pioneer Holding Ltd HKSE:01345
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Shanghai Pioneer Holding (HKSE:01345) Overvalued in 2026?

Based on GuruFocus' analysis, Shanghai Pioneer Holding stock appears to be overvalued. The current stock price of HK$2.15 is trading 19.4% above its estimated GF Value™ of HK$1.80. GuruFocus considers Shanghai Pioneer Holding to be Modestly Overvalued.

Key valuation signals for HKSE:01345:

  • FFO:
  • GF Value™: HK$1.80 vs. price of HK$2.15 (19.4% above fair value)
  • GF Score™: 73/100 with 8 warning signs

No single metric tells the full story. See the HKSE:01345 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Shanghai Pioneer Holding Business Description

Address No.15, Lane 88 Wuwei Road, Putuo District, Shanghai, CHN, 200331
Shanghai Pioneer Holding Ltd is an investment holding company. Along with its subsidiaries, the company is engaged in the marketing, promotion, sales, and channel management service for imported pharmaceutical products and medical devices in China. The company has a portfolio of pharmaceutical products, covering ophthalmology, pain management, cardiovascular, gastroenterology, immunology, gynecology, and other therapeutic areas, and medical devices covering several medical specialties, including ophthalmology, odontology, cardiology and wound care products. The majority of its revenue derives from the Sales of medical equipment and supplies. The group operates mainly in the People's Republic of China.
73GF Score

Get the complete analysis for HKSE:01345

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$2.15
Price
HK$1.80
GF Value